Buttitta F - Search Results

1

Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.

Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Genazzani AR. Gadducci A, et al. Among authors: buttitta f. Anticancer Res. 1998 Sep-Oct;18(5B):3763-5. Anticancer Res. 1998. PMID: 9854491

2

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study.

Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G. Buttitta F, et al. Br J Cancer. 1997;75(2):230-5. doi: 10.1038/bjc.1997.38. Br J Cancer. 1997. PMID: 9010031 Free PMC article.

3

Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.

Gadducci A, Ferdeghini M, Buttitta F, Fanucchi A, Annicchiarico C, Prontera C, Bevilacqua G, Genazzani AR. Gadducci A, et al. Among authors: buttitta f. Anticancer Res. 1996 Nov-Dec;16(6B):3519-23. Anticancer Res. 1996. PMID: 9042215

4

Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.

Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Gagetti O, Bevilacqua G, Genazzani AR. Gadducci A, et al. Among authors: buttitta f. Gynecol Oncol. 1999 Jan;72(1):76-81. doi: 10.1006/gyno.1998.5101. Gynecol Oncol. 1999. PMID: 9889034

5

p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.

Gadducci A, Cianci C, Cosio S, Carnino F, Fanucchi A, Buttitta F, Conte PF, Genazzani AR. Gadducci A, et al. Among authors: buttitta f. Anticancer Res. 2000 Nov-Dec;20(6C):4793-9. Anticancer Res. 2000. PMID: 11205220

6

Evaluation of FHIT gene alterations in ovarian cancer.

Buttitta F, Marchetti A, Radi O, Bertacca G, Pellegrini S, Gadducci A, Genazzani AR, Bevilacqua G. Buttitta F, et al. Br J Cancer. 1998 Apr;77(7):1048-51. doi: 10.1038/bjc.1998.175. Br J Cancer. 1998. PMID: 9569038 Free PMC article.

7

p53 nuclear accumulation in preneoplastic lesions and stage I uterine endometrioid adenocarcinoma.

Buttitta F, Marchetti A, Athanassiadou S, Gadducci A, Bellina S, Cosio S, Mancini F, Genazzani A, Bevilacqua G. Buttitta F, et al. Oncol Rep. 1997 Mar-Apr;4(2):315-8. doi: 10.3892/or.4.2.315. Oncol Rep. 1997. PMID: 21590050

8

Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma.

Buttitta F, Pellegrini C, Marchetti A, Gadducci A, Cosio S, Felicioni L, Barassi F, Salvatore S, Martella C, Coggi G, Bosari S. Buttitta F, et al. J Clin Oncol. 2003 Apr 1;21(7):1320-5. doi: 10.1200/JCO.2003.09.065. J Clin Oncol. 2003. PMID: 12663721

9

Multidrug resistance related genes and p53 expression in human non small cell lung cancer.

Galimberti S, Marchetti A, Buttitta F, Carnicelli V, Pellegrini S, Bevilacqua G, Petrini M. Galimberti S, et al. Among authors: buttitta f. Anticancer Res. 1998 Jul-Aug;18(4C):2973-6. Anticancer Res. 1998. PMID: 9713494

10

p53 mutations and histological type of invasive breast carcinoma.

Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, Callahan R, Bistocchi M. Marchetti A, et al. Among authors: buttitta f. Cancer Res. 1993 Oct 1;53(19):4665-9. Cancer Res. 1993. PMID: 8402644

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters